experimental drug

An experimental drug has blocked the progression of prostate cancer in an animal model with an aggressive form of the disease, new research shows.

The agent, OSU-HDAC42, belongs to a new class of drugs called histone deacetylase (HDAC) inhibitors, compounds designed to reactivate genes that normally protect against cancer but are turned off by the cancer process.

The study showed that the agent kept mice with a precancerous condition from developing advanced prostate cancer.

Data showed that AME-133v had a potent tumor-halting response in patients with follicular lymphoma, a portion of lymphoma cases.

Results add to research showing a new class of monoclonal antibodies like AME-133v may lengthen survival times, according to researchers at the University of Alabama at Birmingham.

Data showed that AME-133v had a potent tumor-halting response in patients with follicular lymphoma, a portion of lymphoma cases.

Results add to research showing a new class of monoclonal antibodies like AME-133v may lengthen survival times, according to researchers at the University of Alabama at Birmingham.

As people age, their brains pay the price -- inflammation goes up, levels of certain neurotransmitters go down, and the result is a plethora of ailments ranging from memory impairment and depression to Alzheimer's and Parkinson's.

But in a long-term study with implications to treat these and other conditions, researchers have found that an experimental drug, taken chronically, has the ability to stem the effects of aging in the rat brain.

Researchers have found that an experimental drug known as SGX393 is effective against Gleevec-resistant chronic myeloid leukemia.

New research gives additional therapeutic tools for even more effective and longer control of chronic myeloid leukemia.